Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills.
According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.
This condition affects more than 6.2 million people in the US alone; it’s also the most common form of dementia and is the sixth leading cause of death in America.
Treatments are available to alleviate Alzheimer’s symptoms, but because they do not affect the underlying causes of the neurodegenerative disease, they’re only a bandaid solution.
Therapies approved by the US Food and Drug Administration include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine, now under AbbVie (NYSE:ABBV).
Although these and other treatments are available, there is no cure for Alzheimer’s, and death is often the result for patients as the disease devastates the brain.
And, unfortunately, Alzheimer’s disease is rising in prevalence. A report from Research and Markets suggests the global Alzheimer’s market will be worth US$9.4 billion by 2027 thanks to the rising need for drugs in development, along with investments made in biomarkers for further development.
Here the Investing News Network takes a look at a...
Read Full Story: https://investingnews.com/daily/life-science-investing/biotech-investing/alzheimers-disease-treatment-stocks/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.